Palo Capital Has Increased C.H. Robinson (CHRW) Position By $333,318; Ecor1 Capital Has Raised Five Prime Therapeutics (FPRX) Position By $605,000

August 4, 2017 - By Henry Gaston

Palo Capital Inc increased C.H. Robinson (CHRW) stake by 16.35% reported in 2016Q4 SEC filing. Palo Capital Inc acquired 4,566 shares as C.H. Robinson (CHRW)’s stock declined 14.80%. The Palo Capital Inc holds 32,495 shares with $2.38M value, up from 27,929 last quarter. C.H. Robinson now has $9.26B valuation. The stock increased 0.14% or $0.09 during the last trading session, reaching $65.7. About 12 shares traded. C.H. Robinson Worldwide Inc (NASDAQ:CHRW) has declined 7.85% since August 4, 2016 and is downtrending. It has underperformed by 24.55% the S&P500.

Ecor1 Capital Llc increased Five Prime Therapeutics Inc (FPRX) stake by 4.22% reported in 2016Q4 SEC filing. Ecor1 Capital Llc acquired 12,100 shares as Five Prime Therapeutics Inc (FPRX)’s stock declined 39.09%. The Ecor1 Capital Llc holds 298,712 shares with $14.97 million value, up from 286,612 last quarter. Five Prime Therapeutics Inc now has $786.72M valuation. The stock increased 0.96% or $0.26 during the last trading session, reaching $27.33. About shares traded. Five Prime Therapeutics Inc (NASDAQ:FPRX) has declined 30.56% since August 4, 2016 and is downtrending. It has underperformed by 47.26% the S&P500.

Investors sentiment decreased to 0.78 in Q4 2016. Its down 0.30, from 1.08 in 2016Q3. It dived, as 43 investors sold CHRW shares while 191 reduced holdings. 52 funds opened positions while 131 raised stakes. 122.38 million shares or 4.77% more from 116.81 million shares in 2016Q3 were reported. Research & Mgmt has 200 shares for 0.01% of their portfolio. Henderson Plc owns 15,225 shares for 0.01% of their portfolio. Guardian Life Ins Of America has invested 0.01% in C.H. Robinson Worldwide Inc (NASDAQ:CHRW). Nikko Asset Americas invested in 15,400 shares or 0.09% of the stock. Natixis Asset reported 2,309 shares. Tokio Marine Asset Communication reported 0.03% in C.H. Robinson Worldwide Inc (NASDAQ:CHRW). Andra Ap holds 0.22% in C.H. Robinson Worldwide Inc (NASDAQ:CHRW) or 107,600 shares. Hightower Advisors Ltd Liability, Illinois-based fund reported 32,482 shares. Jlb & Associate Incorporated invested in 0.15% or 7,401 shares. Sg Americas holds 0.12% in C.H. Robinson Worldwide Inc (NASDAQ:CHRW) or 191,125 shares. Dimensional Fund Advsr LP holds 451,238 shares. 78,864 were accumulated by Capital Mgmt Corp Va. Perella Weinberg Ptnrs Cap Ltd Partnership reported 0.2% of its portfolio in C.H. Robinson Worldwide Inc (NASDAQ:CHRW). Magnetar Limited holds 48,987 shares or 0.05% of its portfolio. Virginia Retirement Et Al owns 198,100 shares or 0.2% of their US portfolio.

Since February 6, 2017, it had 0 insider purchases, and 7 sales for $3.27 million activity. $1.83 million worth of C.H. Robinson Worldwide Inc (NASDAQ:CHRW) was sold by WIEHOFF JOHN on Monday, February 6. On Tuesday, February 28 the insider LEMKE JAMES sold $388,169. 1,300 shares were sold by Freeman Angela K., worth $94,535. LINDBLOOM CHAD sold $281,066 worth of stock or 3,500 shares. 1,079 shares were sold by Biesterfeld Robert C Jr, worth $83,774. Another trade for 4,865 shares valued at $389,784 was sold by Campbell Ben G. $200,435 worth of C.H. Robinson Worldwide Inc (NASDAQ:CHRW) was sold by OBRIEN CHRIS on Wednesday, February 8.

Among 21 analysts covering C.H. Robinson Worldwide (NASDAQ:CHRW), 5 have Buy rating, 6 Sell and 10 Hold. Therefore 24% are positive. C.H. Robinson Worldwide has $220 highest and $55 lowest target. $77.32’s average target is 17.69% above currents $65.7 stock price. C.H. Robinson Worldwide had 51 analyst reports since July 30, 2015 according to SRatingsIntel. BMO Capital Markets initiated the stock with “Outperform” rating in Wednesday, December 9 report. As per Thursday, February 4, the company rating was upgraded by Raymond James. Deutsche Bank maintained the stock with “Hold” rating in Friday, July 21 report. BMO Capital Markets downgraded it to “Market Perform” rating and $74 target in Monday, March 7 report. The firm earned “Buy” rating on Monday, September 28 by BB&T Capital. RBC Capital Markets upgraded the stock to “Outperform” rating in Thursday, January 7 report. The stock has “Neutral” rating by UBS on Thursday, January 7. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, October 26. The rating was maintained by Susquehanna with “Neutral” on Thursday, October 29. BMO Capital Markets maintained it with “Hold” rating and $7000 target in Thursday, July 20 report.

Investors sentiment decreased to 0.74 in 2016 Q4. Its down 0.41, from 1.15 in 2016Q3. It dived, as 19 investors sold FPRX shares while 69 reduced holdings. 16 funds opened positions while 49 raised stakes. 24.63 million shares or 4.67% less from 25.83 million shares in 2016Q3 were reported. Clinton Grp reported 8,175 shares. Northern Trust has invested 0.01% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Piermont Cap Mgmt accumulated 32,504 shares. Proshare Advsr Limited Liability reported 0.01% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Dupont Capital Mngmt Corporation, Delaware-based fund reported 17,629 shares. Victory Cap Mgmt has invested 0.06% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Pura Vida Investments Ltd Limited Liability Company holds 0.26% in Five Prime Therapeutics Inc (NASDAQ:FPRX) or 14,150 shares. Blackrock Fund Advsrs reported 1.22 million shares. Morgan Stanley has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 107,934 shares. Gargoyle Investment Advisor accumulated 6,625 shares. Legal And General Group Inc Incorporated Public Limited Com has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Creative Planning holds 0% or 4,690 shares. 18,525 are held by Manufacturers Life Insur The. Vident Investment Advisory Lc reported 0.39% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Sphera Funds Management Limited has 0.51% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX).

Among 8 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Five Prime Therapeutics had 13 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) earned “Hold” rating by BMO Capital Markets on Monday, June 5. The firm earned “Buy” rating on Wednesday, June 7 by Jefferies. The rating was initiated by Credit Suisse with “Outperform” on Thursday, January 21. The firm has “Outperform” rating given on Friday, March 11 by Credit Suisse. The rating was initiated by Citigroup with “Buy” on Tuesday, October 25. The stock has “Sell” rating by Zacks on Friday, August 21. The stock has “Sell” rating by Zacks on Tuesday, August 11. The firm earned “Buy” rating on Friday, July 31 by Citigroup. The company was maintained on Monday, October 19 by Oppenheimer.

Since March 1, 2017, it had 0 buys, and 1 insider sale for $23,365 activity. RINGO WILLIAM R sold $23,365 worth of stock or 500 shares.